Benjamin F. McGraw
Independent Chairman of the BoardDr. Benjamin F. McGraw, III, also known as Ben, PharmD, is Executive Chairman of Perfuse Therapeutics, Inc. Dr. McGraw has Pharm.D from The University of Tennessee Health Science Center. Dr. McGraw has B.S. from The University of Tennessee Health Science Center. He serves as Independent Chairman of the Board and Director at Evommune Inc. since October 2020. Dr. MCGraw serves as the Chief Executive Officer at Auration Biotech, Inc. and served as its Executive Chairman since 2014. He serves as Chairman and Chief Executive Officer at TheraVida, Inc. He serves as Executive Chairman of the Board at Trefoil Therapeutics, Inc. He serves as a Portfolio Manager at Long Shadows Asset Management, LLC. Dr. McGraw serves on the Board of Directors of Trefoil Therapeutics Inc. Dr. McGraw served as Chief Executive Officer, Executive Chairman and Director of TheraVida, Inc. since 2013 and 2011 respectively. He serves as Venture Partner at Sanderling Ventures. He served as the Chief Executive Officer and President at Urigen Pharmaceuticals, Inc. Dr. McGraw served as the President and Chief Executive Officer of Valentis Inc. since September 1994 and its Executive Chairman since May 1997. He served as the President and Chief Executive Officer at Megabios Corp., since September 1994. Dr. McGraw served as the Chief Financial Officer, Principal Accounting Officer and Executive Director of Valentis Inc., since November 1, 2006. He joined Megabios Corp., in September 1994. In March 1999, Megabios Corp., merged with GeneMedicine Inc., to form Valentis. Prior to Megabios, from July 1989 to November 1990, Dr. McGraw gained experience in R&D as a Vice President of Development for Marion and Marion, Merrell Dow Inc., in business development as Corporate Vice President, Corporate Development at Allergan Inc. from April 1993 to September 1994, served as President of MedTech Trends Inc., from November 1990 to April 1993 and in finance as President of Carerra Capital Management, where he was the fund Manager for a limited Partnership that invested in health care companies, from November 1991 to April 1993. From November 1987 to July 1989, he served as a Vice President of Development at Marion Laboratories Inc. Dr. McGraw served as the Chairman of the Board of Directors of Megabios Inc., since February 1997 and its Director since September 1994. He served as Chairman of the Board of Urigen Pharmaceuticals, Inc., until November 2007 and Director until July 21, 2009. He served as an Independent Chairman at Aerie Pharmaceuticals, Inc. since March 1, 2022 until November 21, 2022 and served as its Principal Financial Officer until March 1, 2022. Dr. McGraw serves as an Executive Director of PolyMASC PLC. Dr. McGraw served as Interim Executive Chairman and Executive Director of the Board at Aerie Pharmaceuticals, Inc. since September 21, 2021. He served as Interim Executive Chairman at Aerie Pharmaceuticals, Inc. from September 2021 through March 01, 2022. He had been an Independent Director of Aerie Pharmaceuticals, Inc. since September 30, 2014 until September 21, 2021 and also served as its Lead Independent Director until September 21, 2021. Dr. McGraw served as a Director of ISTA Pharmaceuticals Inc. since December 2002 and also served as its Director from April 2000 to November 19, 2002.
Positions
- Company NameEvommune, Inc.Stock CodeEVMNPositionIndependent Chairman of the BoardColleagues
- LCLuis C. PenaFounder, President, CEO & Director
- KCKyle CarverChief Financial Officer
- GSGregory S. MossChief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer
- EAEugene Andrew BauerCo-Founder, Chief Medical Officer & Director
- JPJeegar PatelChief Scientific Officer
- DEDavid Eric CohenIndependent Director
- ASArthur S. KirschIndependent Director
